Cleared Traditional

K163083 - VITEK 2 AST-GN Tobramycin (/= 16 ug/mL) (FDA 510(k) Clearance)

Also includes:
VITEK 2 AST-Gram Negative Tobramycin (/=16 ug/mL)
Feb 2017
Decision
90d
Days
Class 2
Risk

K163083 is an FDA 510(k) clearance for the VITEK 2 AST-GN Tobramycin (</=1->/= 16 ug/mL). This device is classified as a System, Test, Automated, Antimicrobial Susceptibility, Short Incubation (Class II - Special Controls, product code LON).

Submitted by bioMerieux, Inc. (Hazelwood, US). The FDA issued a Cleared decision on February 1, 2017, 90 days after receiving the submission on November 3, 2016.

This device falls under the Microbiology FDA review panel. Regulated under 21 CFR 866.1645.

Submission Details

510(k) Number K163083 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received November 03, 2016
Decision Date February 01, 2017
Days to Decision 90 days
Submission Type Traditional
Review Panel Microbiology (MI)
Summary Summary PDF

Device Classification

Product Code LON — System, Test, Automated, Antimicrobial Susceptibility, Short Incubation
Device Class Class II - Special Controls
CFR Regulation 21 CFR 866.1645

Similar Devices — LON System, Test, Automated, Antimicrobial Susceptibility, Short Incubation

All 25
VITEK 2 AST-Gram Negative Cefazolin (=<1-=>32 µg/mL)
K251579 · bioMerieux, Inc. · Aug 2025
BD Phoenix Automated Microbiology System - GN Eravacycline (0.125-2 µg/mL)
K251713 · Becton, Dickinson and Company · Aug 2025
BD Phoenix™ Automated Microbiology System - GN Imipenem-relebactam (0.0625/4 - 16/4 µg/mL)
K250447 · Becton, Dickinson and Company · May 2025
VITEK COMPACT PRO
K234012 · bioMerieux, Inc. · Mar 2025
BD Phoenix™ Automated Microbiology System
K250344 · Becton, Dickinson and Company · Mar 2025
BD Phoenix™ Automated Microbiology System - GN Ciprofloxacin (0.0156–4 µg/mL)
K233986 · Becton, Dickinson and Company · Mar 2024